CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 220 target
Drug / intervention
IDgenetix Neuropsychiatric Test Panelgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02411123
NCT02411123N/ACompleted
CompareCT.gov

Prospective Randomized Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders

AltheaDx·interventional·Posted Apr 8, 2015·Updated Dec 29, 2015

In Brief

A clinical study evaluating IDgenetix Neuropsychiatric Test Panel for Depression and Anxiety. Completed, enrolled 220 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of subjects with the same attributes without the guidance of PGx testing for their treatment. This study will also evaluate whether pharmacogenetic (PGx) testing can reduce adverse drug events, hospitalization rates, hospital length of stay, emergency room visits, disability, death or other serious drug side effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Anxiety
CountriesUnited States
CollaboratorsCarolina Partners in Mental Healthcare

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 8, 2015
Enrollment StartMar 1, 2015
Primary CompletionOct 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.2 years ago

Interventions

IDgenetix Neuropsychiatric Test Panelgenetic

The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.